Charles S. Berkman Sells 8,215 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 8,215 shares of OmniAb stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total value of $30,231.20. Following the completion of the transaction, the insider now directly owns 364,131 shares in the company, valued at $1,340,002.08. This trade represents a 2.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

OmniAb Stock Performance

NASDAQ OABI opened at $3.88 on Friday. The stock has a market cap of $547.93 million, a P/E ratio of -6.26 and a beta of -0.12. OmniAb, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $6.55. The stock has a 50 day simple moving average of $3.49 and a two-hundred day simple moving average of $3.91.

Institutional Trading of OmniAb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Palumbo Wealth Management LLC increased its position in OmniAb by 12.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after purchasing an additional 2,744 shares during the period. Invesco Ltd. boosted its stake in shares of OmniAb by 3.3% during the 4th quarter. Invesco Ltd. now owns 93,653 shares of the company’s stock valued at $332,000 after purchasing an additional 2,997 shares in the last quarter. Connors Investor Services Inc. boosted its stake in shares of OmniAb by 18.4% during the 4th quarter. Connors Investor Services Inc. now owns 29,611 shares of the company’s stock valued at $105,000 after purchasing an additional 4,611 shares in the last quarter. SG Americas Securities LLC increased its position in shares of OmniAb by 16.5% during the fourth quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock valued at $144,000 after buying an additional 5,751 shares during the period. Finally, Sherbrooke Park Advisers LLC raised its stake in OmniAb by 53.5% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company’s stock worth $61,000 after buying an additional 6,001 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th. Benchmark reissued a “buy” rating and set a $8.00 price target on shares of OmniAb in a research report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.